Long-Acting GLP-1 Receptor Agonism Ameliorates Sinoatrial Node Dysfunction by Attenuating Electrophysiological and Structural Remodeling

Background: Sinoatrial node dysfunction (SND) causes bradyarrhythmia, while pacemaker therapy does not reverse injury to the sinoatrial node (SAN). Long-acting GLP-1 receptor agonists (GLP-1RAs) raise heart rate, but whether they can repair an injured SAN in SND remains unknown. Methods: In streptozotocin-induced SND rats, we studied an acute phase (SND, GLP-1RA treatment, glycemic control, and GLP-1R antagonist groups) and a chronic phase (SND, GLP-1RA treatment, and glycemic control groups). Endpoints included heart rate, RR interval, heart rate variability, intrinsic heart rate (IHR), corrected sinus node recovery time after adenosine injection (ADSNRT), SAN transcriptomics, histology and immunofluorescence, HL-1 cell oxidative-stress studies, and public single-cell data. Results: At the acute endpoint, the long-acting GLP-1RA efsubaglutide alfa (eSuba) increased heart rate (372.76 ± 11.06 vs 312.64 ± 22.28 beats/min; P < 0.0001) and IHR (349.45 ± 10.49 vs 234.79 ± 12.29 beats/min; P < 0.0001), and shortened ADSNRT (4.22 ± 2.75 vs 20.68 ± 1.60 s; P = 0.0009); improvements in heart rate (349.05 ± 17.73 vs 266.02 ± 13.52 beats/min; P < 0.0001) and IHR persisted in the chronic phase. SAN transcriptomics showed reversal of extracellular matrix, inflammatory/immune, redox/mitochondrial, glial, and electrical programs. The GLP-1RA reduced collagen deposition and CCR2a+ infiltration, decreased ox-CaMKII/CaMKII, increased SIRT3, restored Cav1.3, Nav1.5, SERCA2a and p-RyR2 (Ser2808), and increased p-PKA/PKA. The glycemic control comparator produced limited improvement, and the GLP-1R antagonist attenuated most effects. Conclusions: Long-acting GLP-1R agonism improves SAN function in SND via glucose-independent attenuation of electrophysiological and structural remodeling, an effect that is at least partly GLP-1R dependent.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-16
DOI
https://doi.org/10.64898/2026.11.13.766590
Primary Topic
Cardiac electrophysiology and arrhythmias
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Long-Acting GLP-1 Receptor Agonism Ameliorates Sinoatrial Node Dysfunction by Attenuating Electrophysiological and Structural Remodeling

Juyi Wan, Hanfeng Liu, Wei Fan, Bin Liao et al.
1 links
bioRxiv (Cold Spring Harbor Laboratory)
Cardiac electrophysiology and arrhythmias
preprint

Long-Acting GLP-1 Receptor Agonism Ameliorates Sinoatrial Node Dysfunction by Attenuating Electrophysiological and Structural Remodeling

Juyi Wan, Hanfeng Liu, Wei Fan, Bin Liao, Can Liu, Rui Zeng, Zhaoting Li, Yangxi Zeng
preprint en

Abstract

Background: Sinoatrial node dysfunction (SND) causes bradyarrhythmia, while pacemaker therapy does not reverse injury to the sinoatrial node (SAN). Long-acting GLP-1 receptor agonists (GLP-1RAs) raise heart rate, but whether they can repair an injured SAN in SND remains unknown. Methods: In streptozotocin-induced SND rats, we studied an acute phase (SND, GLP-1RA treatment, glycemic control, and GLP-1R antagonist groups) and a chronic phase (SND, GLP-1RA treatment, and glycemic control groups). Endpoints included heart rate, RR interval, heart rate variability, intrinsic heart rate (IHR), corrected sinus node recovery time after adenosine injection (ADSNRT), SAN transcriptomics, histology and immunofluorescence, HL-1 cell oxidative-stress studies, and public single-cell data. Results: At the acute endpoint, the long-acting GLP-1RA efsubaglutide alfa (eSuba) increased heart rate (372.76 ± 11.06 vs 312.64 ± 22.28 beats/min; P < 0.0001) and IHR (349.45 ± 10.49 vs 234.79 ± 12.29 beats/min; P < 0.0001), and shortened ADSNRT (4.22 ± 2.75 vs 20.68 ± 1.60 s; P = 0.0009); improvements in heart rate (349.05 ± 17.73 vs 266.02 ± 13.52 beats/min; P < 0.0001) and IHR persisted in the chronic phase. SAN transcriptomics showed reversal of extracellular matrix, inflammatory/immune, redox/mitochondrial, glial, and electrical programs. The GLP-1RA reduced collagen deposition and CCR2a+ infiltration, decreased ox-CaMKII/CaMKII, increased SIRT3, restored Cav1.3, Nav1.5, SERCA2a and p-RyR2 (Ser2808), and increased p-PKA/PKA. The glycemic control comparator produced limited improvement, and the GLP-1R antagonist attenuated most effects. Conclusions: Long-acting GLP-1R agonism improves SAN function in SND via glucose-independent attenuation of electrophysiological and structural remodeling, an effect that is at least partly GLP-1R dependent.

bioRxiv (Cold Spring Harbor Laboratory)
Southwest Medical University (CN), Affiliated Hospital of Southwest Medical University (CN), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
Good health and well-being
Cardiac electrophysiology and arrhythmias
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon